RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.040
0.00 (0.00%)
At close: Nov 5, 2024, 4:00 PM
1.000
-0.040 (-3.85%)
After-hours: Nov 5, 2024, 4:31 PM EST

Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.

RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.
RenovoRx logo
Country United States
Founded 2012
IPO Date Aug 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Shaun Bagai

Contact Details

Address:
4546 El Camino Real, Suite B1
Los Altos, California 94022
United States
Phone 650 284 4433
Website renovorx.com

Stock Details

Ticker Symbol RNXT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $9.00
CIK Code 0001574094
CUSIP Number 75989R107
ISIN Number US75989R1077
Employer ID 27-1448452
SIC Code 2834

Key Executives

Name Position
Shaun R. Bagai Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D. Founder, Chairman of Board and Chief Medical Officer
Ronald B. Kocak CPA, CGMA Vice President, Controller and Principal Accounting Officer
Leesa Gentry Chief Clinical Officer
Ryan Witt Senior Vice President and Head of Corporate Strategy and Partnerships

Latest SEC Filings

Date Type Title
Sep 25, 2024 8-K Current Report
Aug 16, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Jun 7, 2024 8-K Current Report
May 10, 2024 EFFECT Notice of Effectiveness
May 10, 2024 EFFECT Notice of Effectiveness
May 10, 2024 10-Q Quarterly Report
May 10, 2024 424B3 Prospectus
May 10, 2024 424B3 Prospectus
May 3, 2024 8-K Current Report